Sanjivani Paranteral Limited

SANJIVIN

INE860D01013

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:56 07/06/2024 pm IST			5-day change	1st Jan Change
172.2 ^INR	-1.03%		-5.25%	-4.39%

13/05	Sanjivani Paranteral Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI
13/05	Sanjivani Paranteral Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

Sanjivani Paranteral Limited. announced that it has received INR 15 million in funding from Next Orbit Ventures Private Limited

August 19, 2021

On August 19, 2021, Sanjivani Paranteral Limited closed the transaction. The paid-up equity share capital increased from INR 84,983,000 to INR 99,983,000.

Latest news about Sanjivani Paranteral Limited

Sanjivani Paranteral Limited Reports Earnings Results for the Full Year Ended March 31, 2024	13/05	CI
Sanjivani Paranteral Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	13/05	CI
Sanjivani Parenterals CFO Steps Down	08/04	MT
Sanjivani Paranteral Limited Announces Board Changes	08/04	CI
Sanjivani Paranteral Limited Announces CFO Change	08/04	CI
Sanjivani Paranteral Forms New Unit	28/02	MT
Sanjivani Paranteral Limited Appoints Pooja Vijay Gohil as Company Secretary and Compliance Officer	05/02	CI
Sanjivani Paranteral Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	05/02	CI
Sanjivani Paranteral Limited announced that it has received INR 248.0466 million in funding from Nabs Vriddhii LLP, Plasma Commercials Pvt. Ltd., Venus Orchards Pvt. Ltd., Ashika Global Securities Private Limited	05/02	CI
Sanjivani Paranteral Limited announced that it expects to receive INR 248.0346 million in funding from Nabs Vriddhii LLP, Plasma Commercials Pvt.Ltd., Venus Orchards Pvt. Ltd, Ashika Global Securities Private Limited and other investors	19/12	CI
Sanjivani Paranteral Limited Announces Resignation of Ritu Puglia from the Position of the Company Secretary	15/12	CI
Sanjivani Paranteral Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	18/23/18	CI
Sanjivani Paranteral Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	24/23/24	CI
Sanjivani Paranteral Ties Up with Czech Republic-based Alevia Healthcare to Expand Business in EU	09/23/09	MT
Sanjivani Paranteral Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	06/23/06	CI
Sanjivani Paranteral Limited Reports Earnings Results for the Full Year Ended March 31, 2023	06/23/06	CI
Sanjivani Paranteral Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/23/14	CI
Sanjivani Paranteral Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	14/22/14	CI
Sanjivani Paranteral Limited Appoints Monika Amit Singhania as Independent Director	27/22/27	CI
Sanjivani Paranteral Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	08/22/08	CI
Sanjivani Paranteral Limited Announces Appointment of Ritu Puglia as Company Secretary	17/22/17	CI
Sanjivani Paranteral Limited Reports Earnings Results for the Full Year Ended March 31, 2022	17/22/17	CI
Sanjivani Paranteral Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	17/22/17	CI
Sanjivani Paranteral Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	14/22/14	CI
Sanjivani Paranteral Pays $1.2 Million Debt	14/22/14	MT

Chart Sanjivani Paranteral Limited

Duration

Period

More charts

Sanjivani Paranteral Limited is engaged in the business of manufacturing pharmaceutical products. Its product category includes antibiotic, anti-emetic, non-steroidal anti-inflammatory drugs (NSAID) and analgesic, antimalarial, calcium and vitamin, sedative, steroid, cardiovascular, anti-fibrinolytic, anti-coagulant, vasoconstrictor, inotropic agent, anti-spasmodic, multivitamin, nutrition, iron, NSAID and analgesic, analgesic anti spasmodic, analgesic, and NSAID. Its antibiotic includes Netilmicin Sulphate, Amikacin Sulphate, and Gentamycin Sulphate. Its anti-emetic includes Ranitidine Hydrochloride, Metoclopramide, Ondansetron, and Promethazine. Its NSAID and analgesic includes Acetaminophen Injection and Diclofenac Sodium Injection. Its calcium and vitamin include Methylcobalamin 500 mcg/ml and Nicotinic Acid 10 mg/ml. Its sedative includes Midazolam Hydrochloride, Diazepam, and Dobutamine Hydrochloride. Its Iron includes iron Sucrose. Its analgesic includes Metamizole.

Sector

Pharmaceuticals

Calendar

22/07/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SANJIVANI PARANTERAL LIMITED	-4.39%	24.1M
ELI LILLY AND COMPANY	+45.82%	765B
NOVO NORDISK A/S	+40.95%	632B
JOHNSON & JOHNSON	-6.16%	354B
MERCK & CO., INC.	+19.86%	331B
ABBVIE INC.	+9.32%	299B
ASTRAZENECA PLC	+18.45%	248B
ROCHE HOLDING AG	-0.78%	219B
NOVARTIS AG	+11.88%	216B
AMGEN INC.	+5.90%	164B